GENE ONLINE|News &
Investment Trends & Forecasts
[Illustrations] 2026 TechBio Stress Test: Can AI Deliver Real Drugs as Recursion, Insilico Medicine and Schrödinger Take Center Stage
2026-02-06
[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
2026-02-05
[Illustrations] 2026 Obesity’s Second Wave: Market Fragmentation Starts to Challenge First-Generation Dominance
2026-02-05
[Illustrations] 2026 Biopharma’s “Clearing Year”: IRA, BIOSECURE, and the Phase 3 Threshold Becoming the True Litmus Test
2026-02-05
[Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector
2026-01-30
Why System Integration Is Eclipsing the Chip War: AI’s Energy, Infrastructure, and Sovereignty Bottleneck
2026-01-28
From Capacity Upgrades to Tech Licensing: Global Strategies of Samsung Biologics, Celltrion, and Alteogen
2026-01-21
JPM 2026 Reveals Biopharma’s High-Stakes Mix of IPO Risk, Market Turbulence, and Regulation
2026-01-19
Beyond the Main Stage: A Showcase of the Next Wave of Korean Biotech Innovation at JPM Week 2026
2026-01-15
LATEST
Trip.com Group Limited to Release Q4 and Full-Year 2025 Financial Results on February 25, 2026
2026-02-09
FireFox Gold Reports 54.91 g/t Gold Over 1.95 Meters in Northeast Zone Expansion at Mustajärvi Project
2026-02-09
